Skip to main content

platinum

Generic: platinum

platinum: 4 clinical trials tracked.

platinum evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about platinum, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (4)

A Phase 1a/1b Basket Trial of BMS-986504 With Standard-of-Care Therapy For Patients With Select Metastatic MTAP-deleted Solid Tumors

NCT07532902Registry updated 2026-09-16·Phase 1
Recruiting

Primary endpoint: determine a recommended phase II dose (RP2D) of BMS-986504 in combination with standard-of-care therapy

Interventionalopen60 targetStarted 2026-04Completion 2029-047 sites · United StatesMemorial Sloan Kettering Cancer Center

PIb/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of I.V. Olvi-Vec Combined With Platinum Plus Etoposide in Patients With Advanced SCLC Who Are Platinum-recurrent or Platinum-refractory

NCT07136285Registry updated 2025-12-03·Phase 1/Phase 2
Recruiting

Primary endpoint: Evaluate safety of Olvi-Vec in patients from day 1 to end of study

Interventionalopen27 targetStarted 2023-07Completion 2026-122 sites · ChinaNewsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)

NCT04624204Registry updated 2026-09-10·Phase 3
Active, not recruiting

Primary endpoint: Overall Survival: the time from randomization to death due to any cause

InterventionalRandomizedtriple672 targetStarted 2020-12Completion 2027-1050 sites · Australia, Belgium, Bulgaria, Canada…Merck Sharp & Dohme LLC

An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

NCT04420884Registry updated 2026-04-08·Phase 1/Phase 2
Completed

Primary endpoint: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity

Interventionalopen248 enrolledStarted 2020-07Completion 2026-0350 sites · Austria, Canada, China, France…Takeda